Evidence map›Paper›PMID 42438801›Full record

ArticleJCEM case reports2026

Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy.

Taro Fujisawa, Kazuhisa Takami, Mariko Horikawa, Masahiro Yokoyama, Tomoya Kawashima, Akiyoshi Takami

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Taro FujisawaDepartment of Endocrinology and Metabolism/Diabetes Center, Central Japan International Medical Center, Minokamo 505-8510, Japan.ORCID https://orcid.org/0009-0001-4188-5402
Kazuhisa TakamiDepartment of Endocrinology and Metabolism/Diabetes Center, Central Japan International Medical Center, Minokamo 505-8510, Japan.ORCID https://orcid.org/0009-0007-3204-2925
Mariko HorikawaDepartment of Endocrinology and Metabolism/Diabetes Center, Central Japan International Medical Center, Minokamo 505-8510, Japan.
Masahiro YokoyamaDepartment of Endocrinology and Metabolism/Diabetes Center, Central Japan International Medical Center, Minokamo 505-8510, Japan.
Tomoya KawashimaDepartment of Endocrinology and Metabolism/Diabetes Center, Central Japan International Medical Center, Minokamo 505-8510, Japan.
Akiyoshi TakamiDepartment of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan.ORCID https://orcid.org/0000-0002-1822-9976

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type B insulin resistance syndrome (IRS) is a rare autoimmune disorder characterized by severe insulin resistance caused by autoantibodies against the insulin receptor. Clinically, it presents with fluctuating hyperglycemia and hypoglycemia and is frequently associated with other autoimmune diseases. We report a case with the rarely reported combination of type B IRS and aplastic anemia. A 77-year-old woman with obesity presented with abrupt deterioration of glycemic control and bilateral lower extremity edema. Despite the administration of up to 300 units/day of insulin after hospitalization, hyperglycemia remained refractory. Markedly elevated insulin receptor autoantibody titers (85.9%) confirmed the diagnosis of type B IRS. Further evaluation for concomitant pancytopenia revealed aplastic anemia on bone marrow examination. Immunosuppressive therapy with cyclosporine and eltrombopag for aplastic anemia improved the hyperglycemia; however, early morning hypoglycemia, renal dysfunction associated with intravascular volume depletion, and persistent lower extremity edema remained unresolved. The addition of glucocorticoid therapy resulted in rapid clinical improvement and marked reduction in the insulin receptor autoantibody titers (8.6%). This case highlights the importance of early and appropriate immunomodulatory therapy to achieve remission in type B IRS, particularly in patients with multiple concomitant autoimmune diseases.

Indexed as

aplastic anemiaautoimmune diseaseimmunosuppressive therapyinsulin receptor autoantibodytype B insulin resistance syndrome

Identifiers

PMID42438801
PMCPMC13356968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.